RT Conference Proceedings
T1 Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914)
A1 Grande, E.
A1 Garcia-Carbonero, R.
A1 Teule, A.
A1 Benavent Vinuales, M.
A1 Jimenez-Fonseca, P.
A1 Molina-Cerrillo, J.
A1 Lopez, C.
A1 Custodio, A.
A1 Hierro, C.
A1 Gallego, J.
A1 Alonso, V.
A1 Carmona-Bayonas, A.
A1 Llanos, M.
A1 Sevilla, I.
A1 Hernando, J.
A1 Lista, F.
A1 Anton Pascual, B.
A1 Ruffinelli, J. C.
A1 Gallego Jimenez, I.
A1 Capdevila, J.
K1 cabozantinib
K1 Endocrine Gland Neoplasms
AB Antiangiogenic agents have demonstrated antitumor properties in endocrine malignancies regardless of their primary origin. Experience with immune-checkpoint inhibitors is limited in this area and early results when used as single agents are discouraging. The aim of this trial is to assess the efficacy and safety of the combination of cabozantinib and atezolizumab, which may overcome the resistance in previously treated metastatic endocrine tumors .
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-09-21
LK https://hdl.handle.net/10668/27029
UL https://hdl.handle.net/10668/27029
LA en
NO Grande, E., Garcia-Carbonero, R.. Teule, A., Benavent Vinuales, M., Jimenez-Fonseca, P. , Molina-Cerrillo, J., et al . Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914). Annals of Oncology. Septiembre 2021  (32), S624 - S625
DS RISalud
RD Sep 26, 2025